Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Lexicon Pharmaceuticals Inc
LXRX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.52
-0.13
-7.88%
Dern. MÀJ: Oct 16, 7:46 PM
$1.59
-0.06
-3.64%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Lexicon Pharmaceuticals Financials
Lexicon Pharmaceuticals (LXRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 800 percent decrease over earnings of $0.01 per share
Benzinga Newsdesk
PRO
Lexicon Pharmaceuticals Q1 Sales $1.090M Miss $9.380M Estimate
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly sales of $1.090 million which missed the analyst consensus estimate of $9.380 million by 88.38 percent. This is a 13.63 percent decrease over sales of $1.262
Benzinga Newsdesk
Lexicon Pharmaceuticals Q4 Earnings Summary & Key Takeaways
Benzinga Insights
PRO
Lexicon Pharmaceuticals Q4 EPS $(0.04) Beats $(0.07) Estimate, Sales $5.493M Beat $3.142M Estimate
Benzinga Newsdesk
Earnings Scheduled For March 5, 2026
Benzinga Insights
Exploring Lexicon Pharmaceuticals's Earnings Expectations
Benzinga Insights
